Consensus AtriCure, Inc.

Stocks

ATRC

US04963C2098

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 16:00:00 2026-08-13 EDT			5-day change	1st Jan Change
43.49 ^USD	-0.16%		+10.13%	+9.93%

07-30	Atricure Insider Sold Shares Worth $946,000, According to a Recent SEC Filing	MT
07-28	UBS Adjusts Price Target on AtriCure to $50 From $55, Maintains Buy Rating	MT

Evolution of the Average Target: AtriCure, Inc.

Evolution of the Target Price: AtriCure, Inc.

Changes in Analyst Recommendations: AtriCure, Inc.

65ff5b5853504ef0bea518a.1t8xBbPOAerpsPlNW9iOxaT7YzsOcotxHZpmBiyl7Og.rLx2ZoSRWbmm4LsodrH9qemPPElWBdJDe68xNVvfiNG17AdB2p53m4Xhng~fc053bc65a11a94e6eba1ea7f698f4f3

Analysts' recommendations: AtriCure, Inc.

07-28	UBS Adjusts Price Target on AtriCure to $50 From $55, Maintains Buy Rating	MT
02-18	UBS Adjusts AtriCure Price Target to $55 From $60, Maintains Buy Rating	MT
02-18	Oppenheimer Downgrades AtriCure to Market Perform From Outperform	MT
02-11	AtriCure Shares Fall After JPMorgan Downgrade	MT
02-11	Top Midday Decliners	MT
02-11	JPMorgan Downgrades AtriCure to Neutral From Overweight, Adjusts PT to $36 From $48	MT
25-07-30	Needham Raises Price Target on AtriCure to $45 From $44, Keeps Buy Rating	MT
25-07-29	AtriCure Q2 revenue beats estimates	RE
25-04-30	UBS Adjusts Price Target on AtriCure to $58 From $60, Maintains Buy Rating	MT
25-03-28	Canaccord Genuity Adjusts Price Target on AtriCure to $52 From $66, Maintains Buy Rating	MT
25-02-13	Oppenheimer Adjusts AtriCure Price Target to $45 From $36, Maintains Outperform Rating	MT
24-10-30	UBS Adjusts Price Target on AtriCure to $40 From $35, Maintains Buy Rating	MT
24-07-31	Needham Adjusts AtriCure's Price Target to $34 From $40, Keeps Buy Rating	MT
24-05-02	Needham Lowers AtriCure's PT to $40 From $46 Due to Peer Multiple Contraction, Keeps Buy Rating	MT
24-04-23	Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32	MT
24-02-16	UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating	MT
24-02-16	Stifel Adjusts Price Target on AtriCure to $42 From $50, Maintains Buy Rating	MT
24-02-16	Needham Adjusts Price Target on AtriCure to $46 From $44, Keeps Buy Rating	MT
24-01-22	UBS Adjusts AtriCure Price Target to $57 From $56, Maintains Buy Rating	MT
23-10-23	JMP Securities Initiates AtriCure With Market Outperform Rating, Price Target is $60	MT
23-09-29	UBS Initiates AtriCure With Buy Rating, Price Target is $56	MT
23-07-26	Needham Adjusts Price Target on AtriCure to $68 From $60, Maintains Buy Rating	MT
23-05-03	Needham Adjusts Price Target on AtriCure to $60 From $58, Maintains Buy Rating	MT
23-02-22	BTIG Lowers Price Target on AtriCure to $55 From $65, Maintains Buy Rating	MT
23-02-22	Stifel Adjusts Price Target on AtriCure to $48 From $55, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ATRICURE, INC.					+8.66%
	ABBOTT LABORATORIES					+6.77%
	MEDTRONIC PLC					+8.46%
	CENCORA, INC.					+18.59%
	HOYA CORPORATION					+17.26%
	BECTON, DICKINSON AND COMPANY					+5.27%
	DEXCOM, INC.					+2.91%
	MEDLINE INC.					+25.68%
	WEST PHARMACEUTICAL SERVICES, INC.					+14.89%
	TERUMO CORPORATION					+18.35%
	Average					+12.68%
	Weighted average by Cap.					+10.75%